BioCryst Pharmaceuticals Inc. (Nasdaq: BCRX) reported promising results from its experimental flu treatment peramivir sending the stock price soaring $1.73 to close at $5.95.
BioCryst Reports Upbeat Flu Drug Results
July 17, 2009 at 17:24 PM EDT
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.